Birinapant
Based on 44 publication(s) in Google Scholar
Birinapant (TL32711), a bivalent Smac mimetic, is a potent antagonist for XIAP and cIAP1 with Kds of 45 nM and less than 1 nM, respectively. Birinapant (TL32711) induces the autoubiquitylation and proteasomal degradation of cIAP1 and cIAP2 in intact cells, which results in formation of a RIPK1: caspase-8 complex, caspase-8 activation, and induction of tumor cell death. Birinapant (TL32711) targets TRAF2-associated cIAPs and abrogates TNF-induced NF-κB activation.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.70%
- No. CAS: 1260251-31-7
- Fòrmula: C42H56F2N8O6
- Peso molecular:806.94
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Apoptosis Compound Library
HY-L003
-
NF-κB Signaling Compound Library
HY-L014
-
Anti-Cancer Compound Library
HY-L025
-
Clinical Compound Library
HY-L026
-
Antiviral Compound Library
HY-L027
-
Peptidomimetic Library
HY-L033
-
Drug Repurposing Compound Library
HY-L035
-
Anti-COVID-19 Compound Library
HY-L052
-
Protein-protein Interaction Inhibitor Library
HY-L109
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Heterocyclic Compound Library
HY-L138
-
Cell Death Library
HY-L162
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
Clinical Compound Library Plus
HY-L026P
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) Birinapant
More- Cancer Cell. 2024 Dec 9;42(12):2015-2031.e11. [Abstract]
- Cell. 2025 Jun 12;188(12):3219-3237.e18. [Abstract]
- Cell. 2019 Jul 25;178(3):585-599.e15. [Abstract]
- Cancer Res. 2023 Oct 2;83(19):3284-3304. [Abstract]
- Nat Commun. 2025 Mar 8;16(1):2324. [Abstract]
- Nat Commun. 2024 Oct 24;15(1):9189. [Abstract]
- Nat Commun. 2024 Feb 20;15(1):1532. [Abstract]
- Nat Commun. 2023 Sep 20;14(1):5832. [Abstract]
- Adv Sci (Weinh). 2024 Aug 23:e2400156. [Abstract]
- Cell Death Differ. 2025 Oct 22. [Abstract]
- Cell Death Differ. 2021 Oct;28(10):2888-2899. [Abstract]
- Cell Death Dis. 2021 Jun 23;12(7):641. [Abstract]
- Cell Death Dis. 2020 Feb 5;11(2):94. [Abstract]
- Arch Toxicol. 2026 Jun 27. [Abstract]
- Cell Death Discov. 2025 Nov 24;11(1):543. [Abstract]
- Cell Death Discov. 2023 Jul 26;9(1):262. [Abstract]
- Dev Cell. 2019 Oct 21;51(2):277-291.e4. [Abstract]
- Oncogene. 2022 Jul;41(27):3524-3538. [Abstract]
- Leukemia. 2025 Dec 19. [Abstract]
- Mol Ther Oncolytics. 2022 Nov 15:27:288-304. [Abstract]
- EMBO J. 2023 Oct 4;42(19):e113118. [Abstract]
- Front Microbiol. 2018 Sep 19:9:2022. [Abstract]
- Cell Biol Toxicol. 2025 Jan 28;41(1):35. [Abstract]
- Int J Mol Sci. 2023 Oct 20;24(20):15405. [Abstract]
- Cell Oncol (Dordr). 2019 Jun;42(3):319-329. [Abstract]
- Mol Med Rep. 2020 Mar;21(3):1251-1257. [Abstract]
- Exp Neurol. 2024 Nov 25:115072. [Abstract]
- Cancers (Basel). 2022 Mar 19;14(6):1575. [Abstract]
- J Cell Mol Med. 2021 May 3;25(13):6125-6136. [Abstract]
- Aquaculture. 2021, 736595.
- Icahn School of Medicine at Mount Sinai. 2026.
- bioRxiv. 2025 Oct 23.
- bioRxiv. 2025 Sep 24:2025.09.22.677496. [Abstract]
- Patent. US20250127813A1.
- Hong Kong Polytechnic University. 2025.
- University of North Carolina at Chapel Hill. 2024.
- bioRxiv. 2024 Nov 28:2024.11.25.625306. [Abstract]
- University of Cologne. 2024.
- University of Gothenburg. 2023 Jun 27.
- bioRxiv. 2023 Mar 6.
- University of Portland. 2022.
- Patent. US20210269505A1.
- bioRxiv. 2019 Nov.
- University Regensburg. 2017 Jul.
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
-
In Vivo Efficacy Study
-
Flow Cytometry
-
WB
Actividad biológica
Kd: 45 nM (XIAP), <1 nM (cIAP1)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MDA-MB-231 | IC50 |
10 nM
Compound: 4, TL32711
|
Cytotoxicity against cIAP/XIAP-dependent human MDA-MB-231 cells assessed as cell viability after 72 hrs by MTS assay
Cytotoxicity against cIAP/XIAP-dependent human MDA-MB-231 cells assessed as cell viability after 72 hrs by MTS assay
|
[PMID: 25584393] |
Birinapant (TL32711) (30-10000 nM; 24 hours) significantly decreases the viability of SUM190 cells in a dose-dependent manner[1].
?
Birinapant (TL32711) (30-1000 nM; 4 hours) shows a significant decrease in cIAP1 levels and enhanced PARP cleavage, and induces apoptosis[1].
?
Birinapant (TL32711) binds with high affinity to the isolated BIR3 domains of cIAP1, cIAP2, and XIAP and the single BIR domain of ML-IAP and rapidly degrades TRAF2-bound cIAP1 and cIAP2 thereby inhibiting TNF-mediated NF-κB activation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:TRAIL-resistant SUM190 IBC cells
-
Concentration:30, 100, 300, 1000, 10000 nM
-
Incubation Time:24 hours
-
Result:Significantly decreased the viability of SUM190 cells in a dose-dependent manner.
-
Cell Line:SUM190 cells
-
Concentration:30, 300, 1000 nM
-
Incubation Time:4 hours
-
Result:Showed a significant decrease in cIAP1 levels and enhanced PARP cleavage.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female athymic nude mice (low-passage, patient-derived xenotransplant models of ovarian cancer, colorectal cancer, and melanoma)[2]
-
Dosage:30 mg/kg
-
Administration:Intraperitoneal injection; every third day (*5)
-
Result:Resulted in inhibition of tumor growth.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 1260251-31-7
-
Appearance Solid
-
Peso molecular 806.94
-
Fòrmula C42H56F2N8O6
-
Color Off-white to light yellow
-
SMILES
FC1=CC2=C(C=C1)C(C[C@H]3N(C([C@@H](NC([C@@H](NC)C)=O)CC)=O)C[C@@H](O)C3)=C(C(N4)=C(C[C@H]5N(C([C@@H](NC([C@@H](NC)C)=O)CC)=O)C[C@@H](O)C5)C6=C4C=C(F)C=C6)N2
-
Synonyms
TL32711
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (44)
-
Journal Impact Factor
-
Most Recent
-
Cancer Cell
Interleukin-1α release during necrotic-like cell death generates myeloid-driven immunosuppression that restricts anti-tumor immunity. [Abstract]2024 Dec 9;42(12):2015-2031.e11. PMID: 39577420 -
Cell
2025 Jun 12;188(12):3219-3237.e18. PMID: 40250420
Birinapant purchased from MedChemExpress. Usage Cited in: Cell. 2025 Jun 12;188(12):3219-3237.e18. [Abstract]
Viability of shLuc+/Vec-, shCD36+/Vec-, shCD36+/CD36- HCC1806 cells determined by MTT assays after incubation with increasing concentrations of Birinapant.
-
Cell
2019 Jul 25;178(3):585-599.e15. PMID: 31303383
Birinapant purchased from MedChemExpress. Usage Cited in: Cell. 2019 Jul 25;178(3):585-599.e15. [Abstract]
Western blot analysis of polyclonal pools of sgCtrl or sgTRAF2-expressing SK-MEL-23 melanoma cells in the presence or absence of Birinapant, and upon coculture with MART-1 T cell for indicated amounts of time.
-
Cancer Res
Endocrine therapy synergizes with SMAC mimetics to potentiate antigen presentation and tumor regression in hormone receptor-positive breast cancer. [Abstract]2023 Oct 2;83(19):3284-3304. PMID: 37450351
Birinapant purchased from MedChemExpress. Usage Cited in: Cancer Res. 2023 Oct 2;83(19):3284-3304. [Abstract]
Cell growth studies of MCF7 cells treated with vehicle (DMSO), fulvestrant, Birinapant (100 nmol/L), and the combination for 7 days. The number of cells were measured at days 0, 3, 5, and 7.
Birinapant purchased from MedChemExpress. Usage Cited in: Cancer Res. 2023 Oct 2;83(19):3284-3304. [Abstract]
ER+/HER2- PDX tumor growth study. Mice received Birinapant (20 mg/kg I.P., 3d/week for 5 weeks).
Birinapant purchased from MedChemExpress. Usage Cited in: Cancer Res. 2023 Oct 2;83(19):3284-3304. [Abstract]
Median fluorescence intensity (MFI) quantification of MHC-I and PD-L1 levels assessed by flow cytometry in MCF7 cells grown in HD or in the presence of E2. MCF7 cells were pretreated with vehicle, fulvestrant (10 nmol/L), Birinapant (100 nmol/L) and the combination of both drugs for 48 hours.
Birinapant purchased from MedChemExpress. Usage Cited in: Cancer Res. 2023 Oct 2;83(19):3284-3304. [Abstract]
Whole-cell lysates immunoblots of ER, NF-KB subunits, and IFNg target genes in MCF7 cells grown treated with vehicle control (DMSO), Fulvestrant (10 nmol/L), Birinapant (100 nmol/L), and the combination with and without IFNg (10 ng/mL) stimulation for 24 hours.
-
Nat Commun
Uncovering the rewired IAP-JAK regulatory axis as an immune-dependent vulnerability of LKB1-mutant lung cancer. [Abstract]2025 Mar 8;16(1):2324. PMID: 40057483 -
Nat Commun
Chemotherapy resistance in acute myeloid leukemia is mediated by A20 suppression of spontaneous necroptosis. [Abstract]2024 Oct 24;15(1):9189. PMID: 39448591 -
Nat Commun
Plasticity-induced repression of Irf6 underlies acquired resistance to cancer immunotherapy in pancreatic ductal adenocarcinoma. [Abstract]2024 Feb 20;15(1):1532. PMID: 38378697 -
Nat Commun
NLRP3 selectively drives IL-1β secretion by Pseudomonas aeruginosa infected neutrophils and regulates corneal disease severity. [Abstract]2023 Sep 20;14(1):5832. PMID: 37730693 -
Adv Sci (Weinh)
Novel CAR-T Cells Specifically Targeting SIA-CIgG Demonstrate Effective Antitumor Efficacy in Bladder Cancer. [Abstract]2024 Aug 23:e2400156. PMID: 39178136 -
Cell Death Differ
USP13 depletion sensitizes colorectal cancer cells to necroptosis by destabilizing cIAP2 proteins. [Abstract]2025 Oct 22. PMID: 41125793 -
Cell Death Differ
2021 Oct;28(10):2888-2899. PMID: 33953350 -
Cell Death Dis
Clinical stage drugs targeting inhibitor of apoptosis proteins purge episomal Hepatitis B viral genome in preclinical models. [Abstract]2021 Jun 23;12(7):641. PMID: 34162831 -
Cell Death Dis
Reversal of CYLD phosphorylation as a novel therapeutic approach for adult T-cell leukemia/lymphoma (ATLL). [Abstract]2020 Feb 5;11(2):94. PMID: 32024820 -
Arch Toxicol
Species, cell proliferation state and oxygen partial pressure are major factors in the in vitro toxicity of repurposed potential ADPKD drugs in human and murine renal proximal tubule cells. [Abstract]2026 Jun 27. PMID: 42363980 -
Cell Death Discov
RB loss sensitizes triple-negative breast cancer to apoptosis induced by cellular stress. [Abstract]2025 Nov 24;11(1):543. PMID: 41285729 -
Cell Death Discov
5-Iodotubercidin sensitizes cells to RIPK1-dependent necroptosis by interfering with NFκB signaling. [Abstract]2023 Jul 26;9(1):262. PMID: 37495567 -
Dev Cell
Single-Cell and Population-Level Analyses Using Real-Time Kinetic Labeling Couples Proliferation and Cell Death Mechanisms. [Abstract]2019 Oct 21;51(2):277-291.e4. PMID: 31564612 -
Oncogene
RB loss determines selective resistance and novel vulnerabilities in ER-positive breast cancer models. [Abstract]2022 Jul;41(27):3524-3538. PMID: 35676324 -
Leukemia
BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML. [Abstract]2025 Dec 19. PMID: 41419608 -
Mol Ther Oncolytics
The IAP antagonist birinapant enhances chimeric antigen receptor T cell therapy for glioblastoma by overcoming antigen heterogeneity. [Abstract]2022 Nov 15:27:288-304. PMID: 36458202 -
EMBO J
ER stress induces caspase-2-tBID-GSDME-dependent cell death in neurons lytically infected with herpes simplex virus type 2. [Abstract]2023 Oct 4;42(19):e113118. PMID: 37646198 -
Front Microbiol
Combination of a Latency-Reversing Agent With a Smac Mimetic Minimizes Secondary HIV-1 Infection in vitro. [Abstract]2018 Sep 19:9:2022. PMID: 30283406
Birinapant purchased from MedChemExpress. Usage Cited in: Front Microbiol. 2018 Sep 19:9:2022. [Abstract]
ACH-2 cells are exposed to Birinapant (50 nM) in the presence or absence of PEP005 (5 nM), with TNF-α (10 ng/ml) co-treatment for 24 h, and cell lysates are used for WB analysis.
-
Cell Biol Toxicol
Targeting p38γ synergistically enhances sorafenib-induced cytotoxicity in hepatocellular carcinoma. [Abstract]2025 Jan 28;41(1):35. PMID: 39871031 -
Int J Mol Sci
Quaternary Benzophenanthridine Alkaloids Act as Smac Mimetics and Overcome Resistance to Apoptosis. [Abstract]2023 Oct 20;24(20):15405. PMID: 37895085 -
Cell Oncol (Dordr)
The X-linked inhibitor of apoptosis protein (XIAP) is involved in melanoma invasion by regulating cell migration and survival. [Abstract]2019 Jun;42(3):319-329. PMID: 30778852 -
Mol Med Rep
SMAC mimetic birinapant inhibits hepatocellular carcinoma growth by activating the cIAP1/TRAF3 signaling pathway. [Abstract]2020 Mar;21(3):1251-1257. PMID: 31922244 -
Exp Neurol
PGAM5 promotes RIPK1-PANoptosome activity by phosphorylating and activating RIPK1 to mediate PANoptosis after subarachnoid hemorrhage in rats. [Abstract]2024 Nov 25:115072. PMID: 39603487 -
Cancers (Basel)
Identification of New Vulnerabilities in Conjunctival Melanoma Using Image-Based High Content Drug Screening. [Abstract]2022 Mar 19;14(6):1575. PMID: 35326726 -
J Cell Mol Med
cIAP1/2 are involved in the radiosensitizing effect of birinapant on NSCLC cell line in vitro. [Abstract]2021 May 3;25(13):6125-6136. PMID: 33939305 -
-
-
-
bioRxiv
Potentiating CAR-T bystander killing by enhanced Fas/FasL signaling mitigates antigen escape in heterogeneous tumors. [Abstract]2025 Sep 24:2025.09.22.677496. PMID: 41040218 -
-
-
-
bioRxiv
2024 Nov 28:2024.11.25.625306. PMID: 39651304 -
-
-
-
-
-
-
Solvente y solubilidad
DMSO : 125 mg/mL (154.91 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (2.58 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (2.58 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (282 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Allensworth JL, et al. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism. Breast Cancer Res Treat. 2013 Jan;137(2):359-71. [Content Brief]
[2]. Krepler C, et al. The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells. Clin Cancer Res. 2013 Apr 1;19(7):1784-94. [Content Brief]
[3]. Nguyen QD, et al. Temporal and spatial evolution of therapy-induced tumor apoptosis detected by caspase-3-selective molecular imaging. Clin Cancer Res. 2013 Jul 15;19(14):3914-24. [Content Brief]
[4]. Benetatos CA, et al. Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models. Mol Cancer Ther. 2014 Apr;13(4):867-79. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.2392 mL | 6.1962 mL | 12.3925 mL | 30.9812 mL |
| 5 mM | 0.2478 mL | 1.2392 mL | 2.4785 mL | 6.1962 mL | |
| 10 mM | 0.1239 mL | 0.6196 mL | 1.2392 mL | 3.0981 mL | |
| 15 mM | 0.0826 mL | 0.4131 mL | 0.8262 mL | 2.0654 mL | |
| 20 mM | 0.0620 mL | 0.3098 mL | 0.6196 mL | 1.5491 mL | |
| 25 mM | 0.0496 mL | 0.2478 mL | 0.4957 mL | 1.2392 mL | |
| 30 mM | 0.0413 mL | 0.2065 mL | 0.4131 mL | 1.0327 mL | |
| 40 mM | 0.0310 mL | 0.1549 mL | 0.3098 mL | 0.7745 mL | |
| 50 mM | 0.0248 mL | 0.1239 mL | 0.2478 mL | 0.6196 mL | |
| 60 mM | 0.0207 mL | 0.1033 mL | 0.2065 mL | 0.5164 mL | |
| 80 mM | 0.0155 mL | 0.0775 mL | 0.1549 mL | 0.3873 mL | |
| 100 mM | 0.0124 mL | 0.0620 mL | 0.1239 mL | 0.3098 mL |
Birinapant Related Classifications
HY-16591 Related Classifications
Powered by Bioz